Pure and Organic CBD & and Hemp Products

Effective medicine provided by mother nature

  • Powerful relaxant

  • Strong painkiller

  • Stress reduction
  • Energy booster

Why CBD?

More and more renowned scientists worldwide publish their researches on the favorable impact of CBD on the human body. Not only does this natural compound deal with physical symptoms, but also it helps with emotional disorders. Distinctly positive results with no side effects make CBD products nothing but a phenomenal success.

This organic product helps cope with:

  • Tight muscles
  • Joint pain
  • Stress and anxiety
  • Depression
  • Sleep disorder

Range of Products

We have created a range of products so you can pick the most convenient ones depending on your needs and likes.

CBD Capsules Morning/Day/Night:

CBD Capsules

These capsules increase the energy level as you fight stress and sleep disorder. Only 1-2 capsules every day with your supplements will help you address fatigue and anxiety and improve your overall state of health.

Order Now

CBD Tincture

CBD Tincture

No more muscle tension, joints inflammation and backache with this easy-to-use dropper. Combined with coconut oil, CBD Tincture purifies the body and relieves pain. And the bottle is of such a convenient size that you can always take it with you.

Order Now

Pure CBD Freeze

Pure CBD Freeze

Even the most excruciating pain can be dealt with the help of this effective natural CBD-freeze. Once applied on the skin, this product will localize the pain without ever getting into the bloodstream.

Order Now

Pure CBD Lotion

Pure CBD Lotion

This lotion offers you multiple advantages. First, it moisturizes the skin to make elastic. And second, it takes care of the inflammation and pain. Coconut oil and Shia butter is extremely beneficial for the health and beauty of your skin.

Order Now

Conditions helped by cbd oil benefits

in Clinical Epilepsy Evidence

wesst123
05.07.2018

Content:

  • in Clinical Epilepsy Evidence
  • Epilepsy Clinical Trials
  • Definition
  • About 3 percent of persons are diagnosed with epilepsy during their lifetime, but about 70 percent of persons with epilepsy eventually go into. Clinical Trials: Another Option The Epilepsy Therapy Project of the Epilepsy Foundation works to promote the discovery of new treatments for epilepsy and bring. In this video, the Epilepsy Foundation's Chief Scientific Officer Dr. Jacqueline French introduces one of her patients, Sally. You'll hear Sally and her family share.

    in Clinical Epilepsy Evidence

    Double blind, randomized, historical control study of the safety and efficacy of Eslicarbazepine Acetate Monotherapy in subjects with partial epilepsy not well controlled by current antiepileptic drugs. A research study is evaluating an investigational medication in combination with traditional therapies for focal-onset seizures in adults who have had an inadequate response to previous epilepsy treatments.

    The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab mg intravenous IV every 4 weeks reduces the frequency of seizures in adult participants with drug-resistant focal epilepsy. The secondary efficacy objective is to assess the effects of natalizumab versus placebo in drug-resistant focal This is a Phase 2a, open-label study consisting of a screening period of up to 4 weeks and a 4- dose-titration treatment period to dose of up to 10 mg twice daily BID of CX, followed by a 1-week safety follow-up period after the last dose of study medication.

    A Multicenter, Open-label, Non-randomized Trial. A study of a drug to be used in addition with another drug to treat adults with Uncontrolled Partial-onset Seizures. This study will evaluate the effectiveness and safety of an investigational drug, IV ganaxolone, as adjunctive therapy to standard of care to treat subjects with status epilepticus.

    This study is designed to describe the incidence of newborn with uncontrolled seizures. Seizures can be associated with any high-risk factors during perinatal stage and diagnosed by abnormal electrical activity in the brain. In this study researchers will use electroencephalography EEG to determine and monitor newborn with uncontrolled or suspected What is the risk of relapse in persons in remission when withdrawing antiepileptic drugs in partial or generalized epilepsy?

    What are the effects of behavioral and psychological treatments in persons with partial or generalized epilepsy? What are the effects of surgery in persons with drug-resistant temporal lobe epilepsy? Vagus nerve stimulation as adjunctive therapy for drug-resistant partial seizures. What are the effects of surgery in persons with drug-resistant generalized epilepsy?

    Epilepsy is a group of disorders rather than a single disorder. Seizures can be classified as partial or focal categorized as simple partial, complex partial, and secondary generalized tonic-clonic seizures or as generalized categorized as generalized tonic-clonic, absence, myoclonic, tonic, and atonic seizures.

    Temporal lobe epilepsy is a form of partial or focal epilepsy. Persons are considered to have epilepsy if they have had two or more unprovoked seizures.

    Epilepsy is common, with an estimated prevalence in resource-rich countries of five to 10 out of 1, persons, and an annual incidence of 50 out of , persons. About 3 percent of persons will be diagnosed with epilepsy at some time in their lives. Epilepsy is a symptom rather than a disease, and it may be caused by various disorders involving the brain. The causes and risk factors include birth or neonatal injuries, congenital or metabolic disorders, head injuries, tumors, infections of the brain or meninges, genetic defects, degenerative disease of the brain, cerebrovascular disease, and demyelinating disease.

    Epilepsy can be classified by cause. Idiopathic generalized epilepsies e. Symptomatic epilepsies result from a known cerebral abnormality. For example, temporal lobe epilepsy may result from a congenital defect, mesial temporal sclerosis, or a tumor. Cryptogenic epilepsies are those that cannot be classified as idiopathic or symptomatic. About 60 percent of untreated persons have no further seizures during the two years after their first seizure. Prognosis is good for most persons with epilepsy.

    About 70 percent go into remission, defined as being seizure-free for five years on or off treatment. This leaves 20 to 30 percent who develop chronic epilepsy, which is often treated with multiple antiepileptic drugs. Already a member or subscriber? Esclicarbazepine, losigamone, and retigabine are not available in the United States. The medical information contained herein is the most accurate available at the date of publication. Want to use this article elsewhere?

    Diagnosing Lumbar Spinal Stenosis. Nov 15, Issue. Trade-off between benefits and harms Antiepileptic drugs What are the effects of monotherapy in newly diagnosed partial epilepsy?

    Beneficial Addition of second-line drugs allopurinol, esclicarbazepine, gabapentin, lamotrigine, levetiracetam, losigamone, oxcarbazepine, retigabine, tiagabine, topiramate, vigabatrin, or zonisamide What is the risk of relapse in persons in remission when withdrawing antiepileptic drugs in partial or generalized epilepsy?

    Trade-off between benefits and harms Antiepileptic drug withdrawal What are the effects of behavioral and psychological treatments in persons with partial or generalized epilepsy? Likely to be beneficial Educational programs Unknown effectiveness Biofeedback Cognitive behavior therapy Family counseling Relaxation plus behavioral modification therapy Relaxation therapy Yoga What are the effects of surgery in persons with drug-resistant temporal lobe epilepsy?

    Clinical Questions What are the benefits and risks of starting antiepileptic drug treatment after a single seizure? Definition Epilepsy is a group of disorders rather than a single disorder. Incidence and Prevalence Epilepsy is common, with an estimated prevalence in resource-rich countries of five to 10 out of 1, persons, and an annual incidence of 50 out of , persons.

    Epilepsy Clinical Trials

    Epilepsia. Nov;46(11) Brain inflammation in epilepsy: experimental and clinical evidence. Vezzani A(1), Granata T. Author information. Epilepsy Res Suppl. ; Clinical evidence for the progressive nature of epilepsy. Engel J Jr(1). Author information: (1)Department of Neurology, Brain . Inflammation and epilepsy in the developing brain: clinical and experimental evidence. Dupuis N(1), Auvin S. Author information: (1)INSERM.

    Definition



    Comments

    zeno3

    Epilepsia. Nov;46(11) Brain inflammation in epilepsy: experimental and clinical evidence. Vezzani A(1), Granata T. Author information.

    Snipe3422

    Epilepsy Res Suppl. ; Clinical evidence for the progressive nature of epilepsy. Engel J Jr(1). Author information: (1)Department of Neurology, Brain .

    Morduderzhi4

    Inflammation and epilepsy in the developing brain: clinical and experimental evidence. Dupuis N(1), Auvin S. Author information: (1)INSERM.

    olezecka1739258

    Learn about clinical trials and how to find clinical trials for epilepsy.

    Pondfiller13

    Summary: Inflammatory reactions occur in the brain in various CNS diseases, including autoimmune, neurodegenerative, and epileptic.

    jpp123

    Epilepsy Clinical Research Trial Listings in Neurology Family Medicine Genetic Disease on CenterWatch.

    zlobaa

    Researchers are always looking for new ways to treat epilepsy. They try out new medicines and other therapies in studies called clinical trials. If you have.

    Add Comment